Suven Life Sciences
161.64
+13.05(+8.78%)
Market Cap₹3,676.89 Cr
PE Ratio-12.53
IndustryHealthcare
Company Performance:
1D+8.78%
1M-1.92%
6M-39.42%
1Y+23.50%
5Y+97.36%
View Company Insightsright
More news about Suven Life Sciences
11Nov 25
Suven Life Sciences Reports Wider Quarterly Loss of Rs 77.3 Crore
Suven Life Sciences, a biopharmaceutical company, reported a consolidated net loss of Rs 77.30 crore for the latest quarter, up 56% from Rs 49.60 crore in the same period last year. Total revenue decreased by 50% to Rs 2.50 crore, while sales increased by 90% to Rs 1.90 crore. EBITDA worsened to Rs -50.10 crore from Rs -26.50 crore, and operating loss expanded to Rs 50.70 crore from Rs 30.50 crore. Expenses rose by 66.98% to Rs 52.60 crore, contributing to the wider losses.
 no imag found
20Aug 25
Suven Life Sciences Advances Alzheimer's Drug Trial, Completes ₹857 Crore Fundraising
Suven Life Sciences is conducting a phase 3 clinical trial for SUVN-502 (Masupirdine) targeting agitation and aggression in Alzheimer's patients, with results expected by 2027. The company has raised ₹857 crore, split equally between the Chairman's family and external investors, to support ongoing research. Two additional molecules, SUVN-G3031 and SUVN-911, are also in the pipeline with results expected around 2027. The company currently generates no revenue and doesn't expect profitability until a molecule succeeds in trials. Shares closed at ₹236.25, up 2.18%.
 no imag found
13Aug 25
Suven Life Sciences Reports Wider Q1 Net Loss Despite Revenue Growth
Suven Life Sciences reported Q1 financial results with revenue increasing to ₹18.67 crore, up 85.59% year-over-year. However, net loss widened to ₹14.78 crore, nearly double the previous year's loss. Total expenses rose to ₹1,723.44 lakhs, while R&D expenses were ₹518.77 lakhs. The company's operational revenue nearly doubled, but other income decreased significantly.
 no imag found
16Jul 25
Suven Life Sciences Initiates Phase 2B Trial for Novel Depression Treatment
Suven Life Sciences has enrolled the first patient in a Phase 2B clinical trial for Ropanicant, a new drug targeting Major Depressive Disorder (MDD). This milestone marks significant progress in the company's efforts to develop innovative treatments for mental health disorders. The trial aims to evaluate the efficacy and safety of Ropanicant in a larger patient population, building on earlier promising results. This development could potentially position Suven Life Sciences as a key player in the antidepressant market and contribute valuable insights to neuropharmacology.
 no imag found
03Jul 25
Suven Life Sciences Allocates 29.85 Lakh Convertible Warrants to Abakkus Fund
Suven Life Sciences has allocated 29.85 lakh convertible warrants to Abakkus Diversified Alpha Fund, managed by Sunil Singhania. This allocation could potentially lead to changes in shareholding structure, capital infusion, and future equity expansion for the pharmaceutical company.
 no imag found
13May 25
Suven Life Sciences Secures ₹857 Crore Through Preferential Issue, Backed by Market Veterans
Suven Life Sciences has approved a preferential issue of 6.4 crore convertible warrants at ₹134 per warrant, raising up to ₹857 crore. The issue attracted investments from funds managed by market veterans Sunil Singhania and Prashant Jain. The issue price represents a 12.40% discount to the previous closing price. Following the announcement, the company's shares jumped 11.80%, reflecting positive market sentiment.
 no imag found
13May 25
Suven Life Sciences Issues Convertible Warrants and Reports Q4 FY24 Financial Results
Suven Life Sciences has issued 62 lakh equity convertible warrants at Rs. 134 each to two investment funds. The company's Q4 FY24 results show a 59.70% decrease in revenue to ₹2.70 crore and an increased net loss of ₹43.90 crore. For the full FY24, revenue improved by 49.09% to ₹32.80 crore, but the company still reported a net loss of ₹105.10 crore.
 no imag found
Suven Life Sciences
161.64
+13.05
(+8.78%)
1 Year Returns:+23.50%
Industry Peers
Syngene International
470.55
(-1.56%)
Indegene
483.75
(-3.24%)
Suven Life Sciences
161.64
(+8.78%)
Vimta Labs
448.25
(+2.24%)
Take Solutions
42.05
(-1.15%)
Bilcare
66.30
(+0.21%)
Adeshwar Meditex
21.00
(-100.00%)
Vanta Bioscience
19.50
(-100.00%)